Prothena Corporation plc

NASDAQ:PRTA

13.74 (USD) • At close March 14, 2025
Bedrijfsnaam Prothena Corporation plc
Symbool PRTA
Munteenheid USD
Prijs 13.74
Beurswaarde 739,582,980
Dividendpercentage 0%
52-weken bereik 11.7 - 26.75
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gene G. Kinney Ph.D.
Website https://www.prothena.com

Over Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal

Vergelijkbare Aandelen

Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc.

CTKB

4.2 USD

Clover Health Investments, Corp. logo

Clover Health Investments, Corp.

CLOV

3.66 USD

Exscientia plc logo

Exscientia plc

EXAI

4.84 USD

Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc.

PACB

1.22 USD

Veracyte, Inc. logo

Veracyte, Inc.

VCYT

31.51 USD

Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc.

CLDX

20.42 USD

NextGen Healthcare, Inc. logo

NextGen Healthcare, Inc.

NXGN

23.94 USD

P3 Health Partners Inc. logo

P3 Health Partners Inc.

PIII

0.175 USD

CareDx, Inc logo

CareDx, Inc

CDNA

18.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)